Molecular Partners Adjusts FY26 Outlook

02:30 AM EDT, 10/29/2026 (MT Newswires) -- Molecular Partners (MOLN.SW) revised its financial guidance for full-year 2026, according to a Thursday filing. The Swiss biopharmaceutical company now expects total operating expenses of between 50 million francs and 55 million francs, including 5 million francs of non-cash effective costs for share-based payments, IFRS pension accounting, and depreciation. It previously expected operating expenses of between 45 million francs and 55 million francs.